TP53 and metastatic malignant neoplasm in the lymph nodes: After further comparison, similar survival outcomes could be seen between the dMPN0 patients with p53-positive and the muscularis propria tumor invasion with stage 1–2 lymph node metastasis (T2N1–2) patients (84% vs. 80%, P = 0.872) (Fig. 5B), and no significant difference of 5-year OS was found between p53+, dMPN0 patients receiving and those not receiving adjuvant chemotherapy (91% vs. 87%, P = 0.318) (Additional file 1: Fig. S4).